Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited (BITRF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.322x
Based on the latest financial reports, Biotron Limited (BITRF) has a cash flow conversion efficiency ratio of -0.322x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-868.08K) by net assets ($2.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotron Limited - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Biotron Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biotron Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotron Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bioscience Animal Health PCL
BK:BIS
|
0.126x |
|
Refined Metals Corp.
PINK:RFMCF
|
0.642x |
|
WiSA Technologies Inc
NASDAQ:WISA
|
-0.074x |
|
Finlay Minerals Ltd
OTCQB:FYMNF
|
0.037x |
|
Binect AG
XETRA:MA10
|
0.012x |
|
SE-Education Public Company Limited
BK:SE-ED
|
-0.026x |
|
Evolva Holding SA
PINK:ELVAF
|
0.187x |
|
Scandium Canada Ltd
PINK:SCDCF
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Biotron Limited (2001–2025)
The table below shows the annual cash flow conversion efficiency of Biotron Limited from 2001 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $551.89K | $-565.80K | -1.025x | -107.01% |
| 2024-06-30 | $-244.03K | $-3.57 Million | 14.623x | +1510.16% |
| 2023-06-30 | $3.17 Million | $-3.29 Million | -1.037x | +53.49% |
| 2022-06-30 | $1.09 Million | $-2.44 Million | -2.230x | -152.78% |
| 2021-06-30 | $3.86 Million | $-3.41 Million | -0.882x | -99.59% |
| 2020-06-30 | $6.97 Million | $-3.08 Million | -0.442x | -60.48% |
| 2019-06-30 | $5.44 Million | $-1.50 Million | -0.275x | +80.84% |
| 2018-06-30 | $1.28 Million | $-1.84 Million | -1.437x | +26.95% |
| 2017-06-30 | $1.44 Million | $-2.83 Million | -1.968x | -100.34% |
| 2016-06-30 | $3.14 Million | $-3.08 Million | -0.982x | -49.61% |
| 2015-06-30 | $4.14 Million | $-2.72 Million | -0.656x | +69.35% |
| 2014-06-30 | $1.39 Million | $-2.98 Million | -2.142x | -210.15% |
| 2013-06-30 | $4.48 Million | $-3.09 Million | -0.691x | -149.63% |
| 2012-06-30 | $8.27 Million | $-2.29 Million | -0.277x | +66.27% |
| 2011-06-30 | $2.40 Million | $-1.97 Million | -0.820x | +24.19% |
| 2010-06-30 | $1.72 Million | $-1.86 Million | -1.082x | +51.88% |
| 2009-06-30 | $841.51K | $-1.89 Million | -2.249x | -155.50% |
| 2008-06-30 | $1.84 Million | $-1.62 Million | -0.880x | +67.26% |
| 2007-06-30 | $1.36 Million | $-3.65 Million | -2.688x | -576.13% |
| 2006-06-30 | $4.50 Million | $-1.79 Million | -0.398x | +47.04% |
| 2005-06-30 | $2.28 Million | $-1.71 Million | -0.751x | +14.84% |
| 2004-06-30 | $2.96 Million | $-2.61 Million | -0.882x | -344.86% |
| 2002-06-30 | $8.49 Million | $-1.68 Million | -0.198x | -52.42% |
| 2001-06-30 | $10.08 Million | $-1.31 Million | -0.130x | -- |